Neha Korde, MD
Internal Medicine · New York, NYNPI 1962664219
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,183 of the $18,950 with a category attached, or 95.9%. Johnson & Johnson accounts for 74.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $9,688 and has fallen 80.5% since, to $1,888 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $902.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- AstraZeneca$3K
- Janssen Scientific Affairs, LLC$2K
- Adaptive Biotechnologies Corporation$158
- Sanofi$144
- Pfizer$52
- plus $25 from 1 others
Across 175 payments — averaging $121,232 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$11.1M
- Pfizer$7.5M
- Sanofi US Services Inc.$1.1M
- AbbVie$399K
- Janssen Scientific Affairs, LLC$393K
- Acerta Pharma LLC$313K
- plus $414K from 4 others
What the payments were for
- Consulting fees$18,18396%
- Food & beverage$7674%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $14,092 |
| AstraZeneca | 1 | $2,750 |
| Janssen Scientific Affairs, LLC | 2 | $1,729 |
| Adaptive Biotechnologies Corporation | 2 | $158 |
| Sanofi | 1 | $144 |
| Pfizer | 2 | $52 |
| Current Health, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,950 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 139 | $2,507,834 |
| Lenalidomide | 147 | $2,002,408 |
| PomalystPomalidomide | 55 | $935,344 |
| VenclextaVenetoclax | 14 | $196,910 |
| NinlaroIxazomib Citrate | 12 | $146,256 |
| XareltoRivaroxaban | 25 | $19,026 |
| Entecavir | 40 | $9,377 |
| Acyclovir | 270 | $3,987 |
| OxycontinOxycodone Hcl | 13 | $3,918 |
| ValacyclovirValacyclovir Hcl | 18 | $881 |
| Colesevelam Hcl | 13 | $678 |
| Omeprazole | 63 | $659 |
| Tramadol Hcl | 16 | $604 |
| Famotidine | 32 | $396 |
| Pantoprazole Sodium | 19 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $14,092 | $19,02625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.